




Global specialty innovator

Ambition: Return to MSD growth CAGR long-term, supported by External Innovation



Illustration

### Mid-term growth drivers

- CM&E and Fertility portfolio as **resilient backbone** leveraging regional diversification
- Within the **Innovative Franchises** growth of Bavencio<sup>®</sup> and Mavenclad<sup>®</sup> maturing
- Pimicotinib<sup>1</sup> launch opportunity

### Long-term growth led by innovation


- **Expanding in N&I**, developing cladribine capsules in gMG, enpatoran passing fertility
- **Executing Oncology strategy** with early phase DNA damage assets and ADCs

1) Sponsor: Abbisko Therapeutics Co. Ltd., Company holds exclusive license rights to commercialize in China, Hongkong, Macau and Taiwan with option for ROW  
Acronym(s): **MSD** = mid-single digit; **CM&E** = Cardiovascular Metabolism & Endocrinology; **N&I** = Neurology and Immunology; **gMG** = generalized myasthenia gravis; **ADC** = antibody drug conjugate



# Company pipeline

## December 15, 2024



■ Oncology 
 ■ Neurology & Immunology 
 ■ Global Health 
 ▶▶▶ Asset entering new phase<sup>12</sup>
▶ Current phase 
 ■ Previous phase(s)

LA: Locally advanced; Ph1a: phase 1a, dose finding; Ph1b: phase 1b, dose escalation/expansion and signal seeking

<sup>1</sup> Group entered a license agreement with Abbisko Therapeutics Co. Ltd, Shanghai, China, for pimicotinib (ABSK021), which grants a license to commercialize pimicotinib in mainland China, Hong Kong, Macau and Taiwan, with an option for rest of world. <sup>2</sup> Group entered into a licensing agreement with Inspirna, Inc. (New York, NY) for ompenacilid (RGX-202), which grants an exclusive license to ompenacilid outside of the United States and an option to co-develop and co-promote ompenacilid in the US. <sup>3</sup> Includes studies (phase I/II) in collaboration with/ sponsored by external partners, e.g. US National Cancer Institute (NCI). <sup>4</sup> As a single agent and in combination with tuvusertib (ATRi); study includes patients with castration-resistant prostate cancer (CRPC) and epithelial ovarian cancer (EOC). <sup>5</sup> Group entered a collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd., China, including an exclusive license worldwide (ex-China) to develop, manufacture and commercialize M9466/HRS-1167. <sup>6</sup> Patients with soft tissue sarcoma (STS) and glioblastoma. <sup>7</sup> Putative mechanism. <sup>8</sup> Clinical trial passed futility analysis. <sup>9</sup> Dermatomyositis and Polymyositis. <sup>10</sup> Study in healthy volunteers. <sup>11</sup> In combination with pyronaridine in two studies, either in participants with acute uncomplicated malaria, or as chemoprevention in participants with asymptomatic malaria infection. <sup>12</sup> Registered study with open enrollment; subjects may not yet be enrolled.

